By Suprita Anupam
Edited by Neha Mehrotra

Introduction: The Paradox of State-Backed Patient Capital

In November 2025, Prime Minister Narendra Modi introduced an ambitious economic intervention: a massive Rs 1 lakh crore ($12 billion) Research, Development, and Innovation (RDI) fund. Designed to bridge a critical chasm in India’s burgeoning startup economy, the fund was meant to inject much-needed "patient capital" into high-risk sectors traditionally ignored by private venture capital (VC) firms. Fields characterized by extraordinarily long gestation periods—such as DNA-based data storage, drone-defense systems, space-tech satellite manufacturing, and deep-tech bio-engineering—were intended to be the primary beneficiaries.

Yet, nearly a year after its high-profile launch, prominent venture capitalists and alternative investment fund (AIF) managers report a paradox: instead of turbocharging funding in deep-tech and long-horizon innovation, the RDI fund has inadvertently created a prolonged liquidity bottleneck.

Interviews with managing partners overseeing cumulative corpuses ranging from $35 million to over $1 billion, alongside insights from non-banking financial companies (NBFCs), reveal a system mired in administrative friction, bureaucratic delays, and cascading funding freezes. What was promised to be a rapid catalyst for futuristic enterprise has instead forced founders and fund managers into a grueling cycle of administrative limbo.

Chronology of a Disjointed Rollout

The timeline of the RDI fund’s implementation highlights a stark disconnect between political ambition and bureaucratic execution.

• November 2025: Prime Minister Narendra Modi launches the Rs 1 lakh crore ($12 billion) RDI fund under the umbrella of the newly formed Anusandhan National Research Foundation (ANRF). The objective is clear: incentivize domestic R&D and reduce India’s reliance on foreign technology in critical sectors.
• May 2026: Shivkumar Kalyanaraman, CEO of the ANRF, makes a bold public declaration. Speaking with a tone of urgent optimism, Kalyanaraman claims that the first tranches of capital for approved AIFs would be disbursed “in the coming days,” promising that the administrative apparatus would operate at “record speed.”
• January to April 2026: Encouraged by initial announcements, fund managers rush to align their pipelines. A Bengaluru-based fund manager notes, "We submitted our application for RDI funding in January and started calling for RFPs (requests for proposals) and shortlisting startups in April."
• August 2026: The friction points culminate. Rather than celebrating widespread deployment, industry insiders reveal that the funding cycle for several private-public cohorts has been pushed back by nearly a year. Data indicates that even by the first week of August, over 20 additional fund managers were still officially “due to be appointed,” leaving approved startups stranded without capital commitments.

The Anatomy of Delay: Why the Bottleneck Occurred

To understand why a multi-billion-dollar fund has slowed down ecosystem momentum, one must examine the mechanics of how public capital interacts with private venture capital.

Under the design of the RDI fund, ANRF acts as the apex body channeling money through selected Alternative Investment Funds (AIFs) and statutory intermediaries. However, the operational reality has created a cascading series of delays:

1. The Re-Negotiation Trap: Private fund managers who anticipated matching or complementary capital from the RDI fund find themselves unable to close their fundraising rounds. "The entire funding cycle is delayed by almost a year, as we’ll have to renegotiate with private LPs (Limited Partners) after RDIF approval," explains a Bengaluru-based fund manager. Private institutional investors are hesitant to commit capital without knowing the precise disbursement schedules and governance terms of the government co-investment.
2. Shrinking Allocations: The ambitious macro-allocations have faced severe contraction at the micro-execution level. Initial budgetary expectations for FY26 allocated a robust Rs 20,000 crore to the RDI fund. This figure was subsequently scaled down to a modest Rs 3,000 crore.
3. The Disbursement Chokepoint: Of the revised Rs 3,000 crore, the actual flow of funds has slowed to a trickle. The ANRF has disbursed a mere Rs 500 crore to the Technology Development Board (TDB), a statutory body tasked with funding industrial research. While the TDB has committed Rs 2,192 crore to 22 shortlisted startups based on expected inflows, the actual liquidity backing those promises remains constrained.

Bureaucratic Silos and Inter-Agency Friction

The implementation strategy relies heavily on public-sector enterprises and statutory boards to filter and deploy capital. However, structural disconnections between these bodies have exacerbated the crisis.

Consider the case of the Biotechnology Industry Research Assistance Corporation (BIRAC), a public-sector enterprise under the Department of Biotechnology. BIRAC has aggressively moved forward, committing Rs 390 crore to eight high-potential biotech startups. Yet, administrative realities tell a different story: BIRAC has reportedly made these commitments even though it is yet to receive any physical capital allocations from the ANRF.

This creates a dangerous moral hazard and cash-flow mismatch. Startups that secure conditional approvals based on BIRAC’s commitments find themselves unable to pay vendors, hire specialized research talent, or execute lab-scale manufacturing because the underlying government capital remains trapped in bureaucratic clearance channels.

Industry Reactions: Voices from the Frontline

The consensus among institutional investors who spoke anonymously due to ongoing regulatory engagements is uniformly critical of the execution pace, even while praising the original intent of the policy.

"Instead of accelerating funding in the startup ecosystem, the RDI fund has slowed it down," said the managing partner of a venture capital firm that manages a corpus exceeding $1 billion.

Around 12 AIFs—managing corpuses ranging from the mid-market threshold of $35 million up to the billion-dollar mark—along with two major non-banking financial entities, corroborated this perspective. According to these stakeholders, the mere announcement of the RDI fund caused private investors to pause their deployment cycles. Institutional LPs adopted a "wait-and-watch" approach, assuming that state-backed capital would soon subsidize high-risk bets. When the government capital failed to materialize on schedule, private funds found themselves caught between expired fundraising windows and unmet pipeline expectations.

Broader Implications for India’s Deep-Tech Ambitions

India’s macroeconomic aspirations rely heavily on transitioning from an "information technology services" economy to a "deep-technology products" powerhouse. Sectors like drones, defense electronics, quantum computing, and advanced materials cannot survive on short-term venture capital models, which traditionally demand liquidity exits within 5 to 7 years.

The RDI fund was explicitly engineered to solve this temporal mismatch by offering patient capital with gestation horizons stretching across a decade or more. However, the current implementation paralysis threatens to achieve the exact opposite outcome:

• Talent Drain: Deep-tech startups, which require immediate capital to retain elite engineering and scientific talent, are burning through their runways while waiting for government-backed disbursements. Many are being forced to look overseas for early-stage grants and venture backing.
• Loss of Momentum in Strategic Sectors: In domains like national security (drone-defense systems) and space infrastructure (satellites), speed is geopolitical. Delays in funding cycles compromise India’s strategic autonomy and sovereign technological readiness.
• Erosion of Trust in Public-Private Partnerships: Private LPs and foreign institutional investors (FIIs) look closely at execution efficiency when evaluating Indian public policy initiatives. Extended bureaucratic delays risk dampening private sector enthusiasm for future government co-investment models.

Conclusion: The Path Forward

Prime Minister Modi’s vision for the Rs 1 lakh crore RDI fund correctly diagnosed a structural market failure: the absence of domestic risk capital for foundational scientific and technological research.

However, the chasm between policy formulation and ground-level disbursement remains wide. For the ANRF and its participating intermediaries—such as the TDB and BIRAC—the immediate priority must shift from setting ambitious headline targets to untangling bureaucratic red tape, accelerating fund transfers, and restoring the confidence of private co-investors.

Unless administrative bottlenecks are ruthlessly cleared, India’s most promising deep-tech startups risk suffocating not from a lack of vision, but from the very capital meant to save them.